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Resumen
Antecedentes: Los pacientes con mieloma múltiple (MM) que no son elegibles para Trasplante de Médula Ósea han sido 
tratados con melfalán (M) más prednisona (P); sin embargo, el estándar de tratamiento ha cambiado a MP mas talidomida 
(T) debido a un beneficio en supervivencia. Bortezomib (B) y lenalidomida también han surgido como tratamientos efectivos. 
Métodos: Se identificaron los ensayos clínicos aleatorizados y controlados (RCT) obtenidos en la Librería Cochrane, PUBMED, 
LILACS, EMBASE y Scirus. Sólo se consideraron los estudios que compararon melfalán-prednisolona (MP) con cualquier otro 
régimen.
Resultados: Se analizaron 22 RCTs, de 2.159 referencias. MP vs. M mas dexametasona (MD): 3 RCT. No hubo diferencias 
respecto de la supervivencia global (SG), la tasa de respuesta completa (TRC) y la toxicidad hematológica. MD fue superior 
en respuesta parcial (RR 1.54;1.32-1.80) y toxicidad no hematológica RR 2.15;1.36-3.41. MP vs. regímenes basados en tali-
domida: 4 RCT. Se encontraron diferencias a favor de la talidomida respecto de la TRC RR 3.44;1.86-6.39 y respuesta parcial 
(RP) RR 1.67;1.28-2.17. La supervivencia libre de progresión (SLP) fue superior con talidomida (p = 0.02). MP vs. regímenes 
basados en bortezomib: 1 RCT. Se encontraron diferencias significativas a favor de bortezomib en SG HR 0.61;0.42-0.89, 
tiempo a la progresión HR 0.48;0.41-0.56, TRC RR 8.35;4.68-14.89 y RP RR 1.30;1.06-1.59. MP vs. quimioterapia sin M: 3 
RCT. Los esquemas con bendamustina lograron una mayor respuesta completa RR 2.55;1.22-5.30. MP vs. otros: 13 RCT. No 
se encontraron diferencias en la RP, SG ni en los efectos adversos.
Conclusiones: Los pacientes sintomáticos con MM no elegibles para trasplante de médula ósea deben recibir como primera 
línea una combinación de MP con bortezomib o talidomida. Se necesitan más estudios que permitan determinar el beneficio 
terapéutico basado en el fenotipo y la citogenética.
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Abstract
Background: Patients with multiple myeloma (MM) not eligible for SCT have been treated with melphalan (M) plus predni-
sone (P); however, the standard of care has shifted to MP plus thalidomide (T) due to a greater survival benefit. Bortezomib 
(B) and lenalidomide have also emerged as effective agents. 
Methods: Randomized clinical trials (RCT) were identified from the Cochrane Library, PubMed, Lilacs, Embase and Scirus, 
that compare MP to any other regimen. 
Results: Twenty-two trials were included from 2159 potentially eligible references. MP vs. M plus dexamethasone (MD): (3 
RCT) MD was superior in partial response (PR) rate and non-hematological toxicity. MP vs. T-based regimens: (4 RCT) signifi-
cant differences favoring T-based regimens in CR rate, PR rate, and progression-free survival (PFS). MP vs. B based regimens: 
(1 RCT) Significant differences in OS, TTP, CR rate and PR rate favored B-based regimens according to the EBMT criteria. MP 
vs. chemotherapy regimens without M: (3 RCT) A significantly higher number of patients treated with BP achieved a CR. TTP 
was also significantly longer in BP-treated patients (p < 0.02). MP vs. other polychemotherapy regimens: (13 RCT) No signifi-
cant differences in PR, OS, hemathological or other type of toxicity were observed between MP and the other chemotherapy 
regimens. 
Conclusions: Symptomatic MM patients ineligible for SCT should receive as first-line treatment a combination of MP plus B 
or T; these regimens are associated with improved outcome but greater toxicity compared to MP alone. More homogeneous 
clinical trials using a cytogenetic risk approach are required.
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Introduction
Multiple myeloma (MM) is a clonal malignancy char-
acterized by proliferation of abnormal plasma cells that 
impair hematopoiesis, activate bone resorption, and 
secrete a monoclonal paraprotein in serum and urine1. 
MM accounts for about 1% of human neoplasms, 
almost 2% of cancer-related deaths, and 12-15% of 
hematological malignancies2. MM patients with symp-
tomatic disease are usually considered candidates for 
chemotherapy-based treatment3: those who are eligible 
for high-dose therapy followed by stem cell transplanta-
tion (SCT), and those who are ineligible for SCT4. Criteria 
for deciding on eligibility for SCT generally include age, 
performance status (PS), and co-morbid conditions5. 
There is some variability in these parameters and how 
they are applied, since studies examining SCT have been 
carried out with heterogeneous criteria. For example, 
initial studies tended to include patients younger than 
65 years of age, while more recent trials suggest that 
SCT is safe in a selected group of patients over 706. On 
the other hand, since patients with poor-risk chromo-
somal features have a short progression free survival 
(PFS) after SCT, even younger patients with these al-
terations may not be candidates for transplantation7.
Since the 1960s, the standard of care for patients 
ineligible for SCT has been melphalan plus prednisone 
(MP)8; this regimen has the advantages of an oral, out-
patient administration schedule and is generally well-
tolerated. Moreover, a classic study demonstrated that 
while combination chemotherapy tended to induce a 
more rapid response, and a higher overall response rate 
(ORR), these differences did not translate into a survival 
advantage compared to MP9. Though MP has been the 
standard of care for patients with newly diagnosed MM 
ineligible for SCT, other options include dexamethasone 
(D) alone and melphalan plus dexamethasone (MD)4. 
The Intergroupe Francophone du Myélome (IFM) ran-
domized patients who were 65 to 75 years of age to 
receive MP, MD, D alone, or D plus interferon10. While 
none of these regimens induced a significant number 
of complete responses, patients receiving MD had a 
70% ORR, defined as achieving at least a partial re-
sponse (PR), which was significantly higher than that 
seen with any of the other three regimens; however, 
MD was also associated with a greater risk of toxicity, 
especially severe infections. Furthermore, the higher 
response rate with MD did not translate into either a 
significantly better median PFS or overall survival (OS)10. 
Thalidomide has also been added to MP (MPT)11,12. 
Recently, Palumbo et al found that newly diagnosed 
MM patients treated with MPT had a significantly 
higher ORR and longer PFS, as well as a trend to-
wards longer OS, than those treated with MP13. In 
an updated analysis after a median follow-up of 38 
months, median PFS was 21.8 months for MPT and 
14.5 months for MP (p = 0.004), median OS was 45 
months for MPT and 47.6 months for MP (p = 0.79). 
Moreover, PFS was longer with MPT regardless of age, 
serum concentrations of ß2-microglobulin, or high 
International Staging System (ISS)14. However, MPT 
failed to show any significant benefit in OS, which 
